DMY

Three Journal of Pharmaceutical Analysis Studies Explore the Use of Traditional Chinese Medicine for Various Diseases

Retrieved on: 
Friday, January 26, 2024
DMY, Microangiopathy, Neoplasm, VEGF, NAFLD, Radiation, Fe, ATGL, Disease, Lung cancer, TCM, DR, Risk, Quality of life, Diabetic retinopathy, Journal, Nano, Traditional Chinese medicine, Liver, Noetics, Protein, HSP90, CDC37, Non-alcoholic fatty liver disease, Iron

XI'AN, China, Jan. 26, 2024 /PRNewswire/ -- Despite demonstrating significant clinical efficacy against various diseases, the widespread use of Traditional Chinese Medicine (TCM) is still limited.

Key Points: 
  • XI'AN, China, Jan. 26, 2024 /PRNewswire/ -- Despite demonstrating significant clinical efficacy against various diseases, the widespread use of Traditional Chinese Medicine (TCM) is still limited.
  • To address this gap, a new issue of the Journal of Pharmaceutical Analysis presents three independent studies which assessed the potency of TCM-based compounds for various human diseases, along with their molecular mechanisms of action.
  • Oridonin (ORI), a TCM derived from the Chinese herb Rabdosia rubescens, exhibits anti-inflammatory effects.
  • These studies provide a scientific basis for the development of TCM-based compounds into effective targeted therapies for various diseases.